On March 27, 2025 GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, reported that preclinical data on GNX1021 will be presented on April 28 at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025 in Chicago, Illinois (Press release, GlycoNex, MAR 27, 2025, View Source [SID1234651547]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
GNX1021 is an antibody-drug conjugate (ADC) targeting branched Lewis B/Y (bLeB/Y), a unique tumor-associated glycan antigen overexpressed in gastric cancer and other solid tumors. The poster will highlight in vivo efficacy and safety findings from gastric cancer models that demonstrate GNX1021’s tumor control activity.
"We are very pleased that research involving GNX1021, our glycan-targeting ADC, was accepted for presentation at AACR (Free AACR Whitepaper) 2025," said Dr. Mei-Chun Yang, CEO of GlycoNex. "AACR is one of the most influential oncology meetings in the world, and the opportunity to showcase the potential of GNX1021 to treat gastric cancer, an often-deadly cancer with few available therapies, highlights the importance of this program."
Presentation Details:
Event:
American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025
Session Category:
Experimental and Molecular Therapeutics
Session:
Growth Factor Receptors and Other Surface Antigens as Targets for Therapy 1
Abstract Title: (#2932)
GNX1021, a novel ADC targeting glycans with branched Lewis B/Y, demonstrated preclinical tumor control activity in gastric cancer models and favorable safety
Date and Time:
April 28, 2025; 2:00 pm CDT
Location:
McCormick Place Convention Center, Chicago
Poster Section 17, Poster Board 6